Search

Your search keyword '"Roussou, Paraskevi A."' showing total 126 results
Start Over Author "Roussou, Paraskevi A."
126 results on '"Roussou, Paraskevi A."'

1. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies

Author

Vassilakopoulos, Theodoros P., Papageorgiou, Sotirios G., Angelopoulou, Maria K., Chatziioannou, Sophia, Prassopoulos, Vassilios, Karakatsanis, Stamatios, Arapaki, Maria, Mellios, Zois, Sachanas, Sotirios, Kalpadakis, Christina, Katodritou, Eirini, Leonidopoulou, Theoni, Kotsianidis, Ioannis, Hatzimichael, Eleftheria, Kotsopoulou, Maria, Dimou, Maria, Variamis, Eleni, Boutsis, Dimitrios, Terpos, Evangelos, Michali, Evridiki, Karianakis, George, Tsirkinidis, Pantelis, Vadikolia, Chryssa, Poziopoulos, Christos, Pigaditou, Anna, Vrakidou, Effimia, Siakantaris, Marina P., Kyrtsonis, Marie-Christine, Symeonidis, Argyris, Anargyrou, Konstantinos, Papaioannou, Maria, Chatziharissi, Evdoxia, Vervessou, Elissavet, Tsirogianni, Maria, Palassopoulou, Maria, Gainaru, Gabriella, Mainta, Catherine, Tsirigotis, Panagiotis, Assimakopoulou, Theodora, Konstantinidou, Pavlina, Papadaki, Helen, Dimopoulos, Meletios-Athanassios, Pappa, Vassiliki, Karmiris, Themis, Roussou, Paraskevi, Datseris, Ioannis, Panayiotidis, Panayiotis, Konstantopoulos, Kostas, Pangalis, Gerassimos A., and Rondogianni, Phivi

Published
2021
Full Text
View/download PDF

2. Prognostication of the High-Risk WM Patient

Author

Kastritis, Efstathios, Gavriatopoulou, Maria, Kyrtsonis, Marie-Christine, Michael, Michael, Hadjiharissi, Evdoxia, Symeonidis, Argiris, Michalis, Eurydiki, Repoussis, Panagiotis, Tsatalas, Konstantinos, Sioni, Anastasia, Kartasis, Zafiris, Stefanoudaki, Ekaterini, Voulgarelis, Michael, Delimpasi, Sosana, Gika, Dimitra, Vervesou, Elissavet, Konstantopoulos, Konstantinos, Kokkini, Garyfalia, Zomas, Athanasios, Roussou, Paraskevi, Anagnostopoulos, Nikolaos, Economopoulos, Theofanis, Terpos, Evangelos, Zervas, Konstantinos, and Dimopoulos, Meletios A.

Published
2011
Full Text
View/download PDF

3. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma

Author

KARAKATSANIS, STAMATIS J., primary, BOUZANI, MARIA, additional, SYMEONIDIS, ARGYRIS, additional, ANGELOPOULOU, MARIA K., additional, PAPAGEORGIOU, SOTIRIOS G., additional, MICHAIL, MICHAIL, additional, GAINARU, GABRIELLA, additional, KOURTI, GEORGIA, additional, SACHANAS, SOTIRIOS, additional, KALPADAKIS, CHRISTINA, additional, KATODRITOU, EIRINI, additional, LEONIDOPOULOU, THEONI, additional, KOTSIANIDIS, IOANNIS, additional, HATZIMICHAEL, ELEFTHERIA, additional, KOTSOPOULOU, MARIA, additional, DIMOU, MARIA, additional, VARIAMIS, ELENI, additional, BOUTSIS, DIMITRIOS, additional, KANELLIAS, NICK, additional, DIMOPOULOU, MARIA N., additional, MICHALI, EVRIDIKI, additional, KARIANAKIS, GEORGE, additional, TSIRKINIDIS, PANTELIS, additional, VADIKOLIA, CHRYSSA, additional, POZIOPOULOS, CHRISTOS, additional, PIGADITOU, ANNA, additional, VRAKIDOU, EFFIMIA, additional, ECONOMOPOULOS, THEOPHANIS, additional, KYRIAZOPOULOU, LYDIA, additional, SIAKANTARIS, MARINA P., additional, KYRTSONIS, MARIE-CHRISTINE, additional, ANARGYROU, KONSTANTINOS, additional, PAPAIOANNOU, MARIA, additional, HATJIHARISSI, EVDOXIA, additional, VERVESSOU, ELISSAVET, additional, TSIROGIANNI, MARIA, additional, PALASSOPOULOU, MARIA, additional, STEFANOUDAKI, EKATERINI, additional, ZIKOS, PANAYIOTIS, additional, TSIRIGOTIS, PANAYIOTIS, additional, TSOUROUFLIS, GERASSIMOS, additional, ASSIMAKOPOULOU, THEODORA, additional, VERROU, EVGENIA, additional, PAPADAKI, HELEN, additional, LAMPROPOULOU, POLIXENI, additional, DIMOPOULOS, MELETIOS-ATHANASIOS, additional, PAPPA, VASSILIKI, additional, KONSTANTOPOULOS, KOSTAS, additional, KARMIRIS, THEMIS, additional, ROUSSOU, PARASKEVI, additional, PANAYIOTIDIS, PANAYIOTIS, additional, PANGALIS, GERASSIMOS A., additional, and VASSILAKOPOULOS, THEODOROS P., additional

Published
2022
Full Text
View/download PDF

4. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

Author

Kastritis, Efstathios, Kyrtsonis, Marie-Christine, Hadjiharissi, Evdoxia, Symeonidis, Argyris, Michalis, Evridiki, Repoussis, Panagiotis, Tsatalas, Constantinos, Michael, Michael, Sioni, Anastasia, Kartasis, Zafiris, Stefanoudaki, Ekaterini, Voulgarelis, Michail, Delimpasi, Sossana, Gavriatopoulou, Maria, Koulieris, Efstathios, Gika, Dimitra, Zomas, Athanasios, Roussou, Paraskevi, Anagnostopoulos, Nikolaos, Economopoulos, Theophanis, Terpos, Evangelos, Zervas, Konstantinos, and Dimopoulos, Meletios A.

Published
2010
Full Text
View/download PDF

5. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

Author

Vassilakopoulos, Theodoros P., primary, Michail, Michail, additional, Papageorgiou, Sotirios, additional, Kourti, Georgia, additional, Angelopoulou, Maria K., additional, Panitsas, Fotios, additional, Sachanas, Sotirios, additional, Kalpadakis, Christina, additional, Katodritou, Eirini, additional, Leonidopoulou, Theoni, additional, Kotsianidis, Ioannis, additional, Hatzimichael, Eleftheria, additional, Kotsopoulou, Maria, additional, Dimou, Maria, additional, Variamis, Eleni, additional, Boutsis, Dimitrios, additional, Terpos, Evangelos, additional, Dimopoulou, Maria N., additional, Karakatsanis, Stamatios, additional, Michalis, Eurydiki, additional, Karianakis, George, additional, Tsirkinidis, Pantelis, additional, Vadikolia, Chryssa, additional, Poziopoulos, Christos, additional, Pigaditou, Anna, additional, Vrakidou, Effimia, additional, Economopoulos, Theophanis, additional, Kyriazopoulou, Lydia, additional, Siakantaris, Marina P., additional, Kyrtsonis, Marie-Christine, additional, Symeonidis, Argyris, additional, Anargyrou, Konstantinos, additional, Papaioannou, Maria, additional, Hatjiharissi, Evdoxia, additional, Vervessou, Elissavet, additional, Tsirogianni, Maria, additional, Palassopoulou, Maria, additional, Gainaru, Gabriella, additional, Stefanoudaki, Ekaterini, additional, Zikos, Panayiotis, additional, Tsirigotis, Panayiotis, additional, Tsourouflis, Gerasimos, additional, Assimakopoulou, Theodora, additional, Konstantinidou, Pavlina, additional, Papadaki, Helen A., additional, Megalakaki, Katerina, additional, Dimopoulos, Meletios-Athanasios, additional, Pappa, Vassiliki, additional, Karmiris, Themis, additional, Roussou, Paraskevi, additional, Panayiotidis, Panayiotis, additional, Konstantopoulos, Kostas, additional, and Pangalis, Gerassimos A., additional

Published
2021
Full Text
View/download PDF

6. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

Author

Vassilakopoulos, Theodoros P. Michail, Michail Papageorgiou, Sotirios Kourti, Georgia Angelopoulou, Maria K. Panitsas, Fotios Sachanas, Sotirios Kalpadakis, Christina Katodritou, Eirini Leonidopoulou, Theoni Kotsianidis, Ioannis and Hatzimichael, Eleftheria Kotsopoulou, Maria Dimou, Maria and Variamis, Eleni Boutsis, Dimitrios Terpos, Evangelos and Dimopoulou, Maria N. Karakatsanis, Stamatios Michalis, Eurydiki and Karianakis, George Tsirkinidis, Pantelis Vadikolia, Chryssa and Poziopoulos, Christos Pigaditou, Anna Vrakidou, Effimia and Economopoulos, Theophanis Kyriazopoulou, Lydia Siakantaris, Marina P. Kyrtsonis, Marie-Christine Symeonidis, Argyris and Anargyrou, Konstantinos Papaioannou, Maria Hatjiharissi, Evdoxia and Vervessou, Elissavet Tsirogianni, Maria Palassopoulou, Maria and Gainaru, Gabriella Stefanoudaki, Ekaterini Zikos, Panayiotis and Tsirigotis, Panayiotis Tsourouflis, Gerasimos and Assimakopoulou, Theodora Konstantinidou, Pavlina Papadaki, Helen A. Megalakaki, Katerina Dimopoulos, Meletios-Athanasios and Pappa, Vassiliki Karmiris, Themis Roussou, Paraskevi and Panayiotidis, Panayiotis Konstantopoulos, Kostas Pangalis, Gerassimos A.

Subjects
hemic and lymphatic diseases, Health Sciences, Επιστήμες Υγείας
Abstract

Background R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective but also more toxic than R-CHOP. Reliable prognostic classification is needed to guide treatment decisions. Materials and Methods We analyzed the impact of clinical prognostic factors on the outcome of 332 PMLBCL patients = 2 times upper limit of normal (model A) were significantly associated with FFP; E/IV and bulky disease (model B) were associated with LSS. Both models performed better than the International Prognostic Index (IPI) and the age-adjusted IPI by Harrel’s C rank parameter and Akaike information criterion. Both models A and B defined high-risk subgroups (13%-27% of patients [pts]) with approximately 19%-23% lymphoma-related mortality. They also defined subgroups composing approximately one-fourth or one-half of the patients, with 11% risk of failure and only 1% or 4% 5-year lymphoma-related mortality. Conclusion The combination of E/IV with either bulky disease or LDH >= 2 times upper limit of normal defined high-risk but not very-high-risk subgroups. More importantly, their absence defined subgroups comprising approximately one-fourth or one-half of the pts, with 11% risk of failure and minimal lymphoma-related mortality, who may not need more intensive treatment such as R-da-EPOCH. Implications for Practice By analyzing the impact of baseline clinical characteristics on outcomes of a large cohort of patients with primary mediastinal large B-cell lymphoma homogeneously treated with R-CHOP with or without radiotherapy, we developed novel prognostic indices which can aid in deciding which patients can be adequately treated with R-CHOP and do not need more intensive regimens such as R-da-EPOCH. The new indices consist of objectively determined characteristics (extranodal disease or stage IV, bulky disease, and markedly elevated serum lactate dehydrogenase), which are readily available from standard initial staging procedures and offer better discrimination compared with established risk scores (International Prognostic Index [IPI] and age-adjusted IPI).

Published
2021

9. Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection

Author

Kountouras, Dimitrios, Tsagarakis, Nikolaos J., Fatourou, Evangelia, Dalagiorgos, Efthimios, Chrysanthos, Nikolaos, Berdoussi, Helen, Vgontza, Niki, Karagiorga, Markissia, Lagiandreou, Athanasios, Kaligeros, Konstantinos, Voskaridou, Ersi, Roussou, Paraskevi, Diamanti-Kandarakis, Evanthia, and Koskinas, John

Published
2013
Full Text
View/download PDF

11. Adrenal function in non-septic long-stay critically ill patients: evaluation with the low-dose (1 Aug) corticotropin stimulation test

Author

Dimopoulou, Ioanna, Ilias, Ioannis, Roussou, Paraskevi, Gavala, Alexandra, Malefaki, Adigoni, Milou, Ema, Pitaridis, Marinos, and Roussos, Charis

Subjects
Interleukin-6 -- Physiological aspects, Adrenal cortex -- Physiological aspects, ACTH -- Physiological aspects, Critically ill -- Physiological aspects, Critically ill -- Research, Health care industry
Abstract

Byline: Ioanna Dimopoulou (1), Ioannis Ilias (2), Paraskevi Roussou (3), Alexandra Gavala (1), Adigoni Malefaki (1), Ema Milou (1), Marinos Pitaridis (1), Charis Roussos (1) Keywords: Protracted critical illness Adrenocortical function Low-dose ACTH test Cortisol Interleukin-6 Outcome Abstract: Abstract Objective. To investigate the adrenal function in non-septic, long-stay critically ill patients. Design. Prospective, consecutive study. Setting. General intensive care unit in a university hospital. Patients. Forty-three non-septic patients with protracted critical illness. Interventions. A morning blood sample was first obtained to measure baseline plasma cortisol. Subsequently, 1 Aug of corticotropin (ACTH, Synacthene) was injected intravenously and 30 min later a second blood sample was drawn to determine stimulated plasma cortisol. Patients having a stimulated cortisol level of at least 18 Aug/dl were defined as responders. In 36 patients, morning interleukin-6 (IL-6) was also measured. Measurements and results. Baseline and stimulated plasma cortisol were 16.8+-4.1 Aug/dl and 21.2+-5.1 Aug/dl, respectively. Interleukin-6 was high (median 39.3 pg/ml, interquartile range 24.9--86.6 pg/ml) and correlated negatively with stimulated plasma cortisol (r=--0.40, p Conclusions. Circulating plasma IL-6 levels are high during protracted critical illness, and are partially responsible for the relative adrenal insufficiency found in a subset of severely ill patients. Author Affiliation: (1) Department of Critical Care Medicine, Evangelismos Hospital, Medical School, National & Kapodistrian University of Athens, 45-47 Ipsilandou Street, Athens 106 75, Greece (2) Second Department of Endocrinology, Alexandra Hospital, Medical School, National & Kapodistrian University of Athens, 80 V. Sofias Avenue, Athens 115 28, Greece (3) Third Department of Internal Medicine, Athens Chest Hospital, Medical School, National & Kapodistrian University of Athens, 152 Mesogion Avenue, Athens 115 27, Greece (4) Address for correspondence: 2 Pesmazoglou Street, 14 561 Kifissia, Athens, Greece Article History: Received Date: 26/11/2001 Accepted Date: 06/05/2002 Article note: Electronic Publication

Published
2002

12. No significant improvement in the outcome of patients with Waldenströmʼs macroglobulinemia treated over the last 25 years

Author

Kastritis, Efstathios, Kyrtsonis, Marie-Christine, Hatjiharissi, Evdoxia, Symeonidis, Argiris, Michalis, Eurydiki, Repoussis, Panagiotis, Tsatalas, Konstantinos, Michael, Michael, Sioni, Anastasia, Kartasis, Zafiris, Stefanoudaki, Ekaterini, Voulgarelis, Michael, Delimpasi, Sosana, Gavriatopoulou, Maria, Koulieris, Efstathios, Gika, Dimitra, Vervesou, Elissavet, Konstantopoulos, Konstantinos, Kokkini, Garyfalia, Zomas, Athanasios, Roussou, Paraskevi, Anagnostopoulos, Nikolaos, Economopoulos, Theofanis, Terpos, Evangelos, Zervas, Konstantinos, and Dimopoulos, Meletios A.

Published
2011
Full Text
View/download PDF

15. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma

Author

Vassilakopoulos, Theodoros P., Angelopoulou, Maria K., Constantinou, Nikos, Karmiris, Themistoklis, Repoussis, Panayiotis, Roussou, Paraskevi, Siakantaris, Marina P., Korkolopoulou, Penelope, Kyrtsonis, Marie-Christine, Kokoris, Styliani I., Dimopoulou, Maria N., Variamis, Eleni, Viniou, Nora-Athina, Konstantopoulos, Konstantinos, Dimitriadou, Evangelia M., Androulaki, Athina, Patsouris, Efstratios, Doussis-Anagnostopoulou, Ipatia A., Panayiotidis, Panayiotis, Boussiotis, Vassiliki A., Kittas, Christos, and Pangalis, Gerassimos A.

Published
2005
Full Text
View/download PDF

16. Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group

Author

Galanopoulos, Athanasios G., Symeonidis, Argyris, Kourakli, Aleka, Papadaki, Eleni A, Tsaftaridis, Panagiotis, Terpos, Evangelos, Aktipi, Anthi, Roussou, Paraskevi, Protopappa, Maria, Pappaioannou, Maria, Zikos, Panagiotis, Speletas, Mattheos, Parcharidou, Agapi, Laoutaris, Nikolaos, Anagnostopoulos, Nikolaos I., Meletis, John, Pangalis, Gerasimos A., and Zoumbos, Nikolaos

Published
2007

18. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis

Author

Tsirigotis, Panagiotis Vassilakopoulos, Theodoros Batsis, Ioannis Bousiou, Zoi Gkirkas, Konstantinos Sakellari, Ioanna and Kaloyannidis, Panayotis Roussou, Paraskevi Pangalis, Gerassimos A. Moschogiannis, Maria Vassilopoulos, George and Repousis, Panagiotis Megalakaki, Aekaterini Michalis, Eurydiki and Kalpadakis, Christina Papadaki, Helen A. Kotsianidis, Ioannis Hatzimichael, Eleftheria Spyridonidis, Alexandros and Anargyrou, Konstantinos Poulakidas, Elias Giannoullia, Panagiota and Apostolidis, Ioannis Stamouli, Maria Konstantopoulos, Konstantinos Pappa, Vassiliki Panayiotidis, Panayiotis and Harhalakis, Nikolaos Anagnostopoulos, Achilles Angelopoulou, Maria

Abstract

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after autologous stem cell transplantation (auto-SCT) is poor. Recently, the anti-CD30 monoclonal antibody-drug conjugate, brentuximab vedotin (BV), has shown remarkable activity in the setting of R/R cHL. In the pivotal phase II study, BV produced an overall response rate of 75% and a median progression-free survival of 6.7months. Although these results have been reproduced by large registry studies, the impact of BV on the overall survival (OS) of patients with R/R cHL has not been addressed so far. The aim of this study was to examine the impact of BV on OS in the setting of post auto-SCT R/R cHL. Analysis was performed in a group of patients with R/R cHL after a previous auto-SCT reported in the Greek registry during the last 2 decades. By using a multivariate model and censoring patients at the time of subsequent allo-SCT or treatment with immune checkpoint inhibitors, we showed that treatment with BV in the posttransplant relapse setting has a positive impact on the outcome and results in significant improvement of OS. To our knowledge, this the first published study, addressing the impact of BV on the OS in the setting of posttransplant relapse.

Published
2018

20. Dimethylarginines in acute myocardial infarction: Association with lifestyle, sociodemographic, and somatometric factors.

Author

Chalioti, Varvara-Maria, Giannakoulis, Vassilis, Papoutsi, Eleni, Megalou, Aikaterini, Kritikos, Konstantinos, Konstantopoulos, Panagiotis, Roussou, Paraskevi, Toutouzas, Konstantinos, and Perrea, Despina

Subjects
MYOCARDIAL infarction, ASYMMETRIC dimethylarginine, FOOD habits, HOSPITAL admission & discharge, C-reactive protein
Abstract

Background: Recent findings associate asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) with the prognosis of acute myocardial infarction (AMI). The purpose of the current study was to associate patients' lifestyle, sociodemographic, and somatometric characteristics with the time course of ADMA and SDMA concentrations in the serum of AMI patients. Patients and Methods: In the serum of 66 AMI patients, ADMA, SDMA, troponin T, and C-reactive protein (CRP) were measured upon hospital admission (<24 h) and on the 3rd day following. Lifestyle, sociodemographic, and somatometric characteristics were obtained through a questionnaire, filled on patient discharge. Results: ADMA concentrations on the 1st day positively correlated with daily reported hours of sleep (+0.497, P < 0.001) and delivery or eating out frequency (+0.285, P = 0.02), whereas it negatively correlated with reported physical condition (-0.304, P = 0.013). A personal history of hypertension indicated higher 1st-day ADMA concentration (1.818 vs 1.568, P = 0.042). Age positively correlated with 1st-day SDMA (+0.320, P = 0.009). All of the biomarker concentrations were reduced on the 3rd day measurements (P < 0.001). Self-reported lifetime minimum BMI positively correlated with either absolute (r = +0.366, P = 0.009) or percentage (r = +0.262, P = 0.045) ADMA reduction. A daily sleep in 5–8-h range was inversely correlated with percentage (-0.410, P = 0.001) or absolute (r = -0.369, P = 0.002) SDMA reduction. Conclusions: Modifiable factors such as BMI, eating habits, physical condition, and sleep seem to affect the baseline levels or time course of ADMA and SDMA in AMI patients. Changes in these factors may affect AMI prognosis by altering dimethylarginine levels. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

21. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis

Author

Tsirigotis, Panagiotis, primary, Vassilakopoulos, Theodoros, additional, Batsis, Ioannis, additional, Bousiou, Zoi, additional, Gkirkas, Konstantinos, additional, Sakellari, Ioanna, additional, Kaloyannidis, Panayotis, additional, Roussou, Paraskevi, additional, Pangalis, Gerassimos A., additional, Moschogiannis, Maria, additional, Vassilopoulos, George, additional, Repousis, Panagiotis, additional, Megalakaki, Aekaterini, additional, Michalis, Eurydiki, additional, Kalpadakis, Christina, additional, Papadaki, Helen A., additional, Kotsianidis, Ioannis, additional, Hatzimichael, Eleftheria, additional, Spyridonidis, Alexandros, additional, Anargyrou, Konstantinos, additional, Poulakidas, Elias, additional, Giannoullia, Panagiota, additional, Apostolidis, Ioannis, additional, Stamouli, Maria, additional, Konstantopoulos, Konstantinos, additional, Pappa, Vassiliki, additional, Panayiotidis, Panayiotis, additional, Harhalakis, Nikolaos, additional, Anagnostopoulos, Achilles, additional, and Angelopoulou, Maria, additional

Published
2018
Full Text
View/download PDF

24. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

Author

Angelopoulou, Maria K., primary, Vassilakopoulos, Theodoros P., additional, Batsis, Ioannis, additional, Sakellari, Ioanna, additional, Gkirkas, Konstantinos, additional, Pappa, Vasiliki, additional, Giannoulia, Panagiota, additional, Apostolidis, Ioannis, additional, Apostolopoulos, Christos, additional, Roussou, Paraskevi, additional, Panayiotidis, Panayiotis, additional, Dimou, Maria, additional, Kyrtsonis, Marie-Christine, additional, Palassopoulou, Maria, additional, Vassilopoulos, Georgios, additional, Moschogiannis, Maria, additional, Kalpadakis, Christina, additional, Margaritis, Dimitrios, additional, Spyridonidis, Alexander, additional, Michalis, Eurydiki, additional, Anargyrou, Konstantinos, additional, Repousis, Panagiotis, additional, Hatzimichael, Eleutheria, additional, Bousiou, Zoi, additional, Poulakidas, Elias, additional, Grentzelias, Dimitrios, additional, Harhalakis, Nikolaos, additional, Pangalis, Gerassimos A., additional, Anagnostopoulos, Achilles, additional, and Tsirigotis, Panagiotis, additional

Published
2017
Full Text
View/download PDF

25. Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group

Author

Galanopoulos, Athanasios, primary, Kontos, Christos K., additional, Viniou, Nora-Athina, additional, Kotsianidis, Ioannis, additional, Pappa, Vassiliki, additional, Kourakli, Aleka, additional, Pouli, Anastasia, additional, Panayiotidis, Panayiotis, additional, Roussou, Paraskevi, additional, Zafeiropoulou, Kalliopi, additional, Karakatsanis, Stamatis, additional, Dimou, Maria, additional, Vardi, Anna, additional, Vassilakopoulos, Theodoros, additional, Tsokanas, Dimitris, additional, Hatzimichael, Eleftheria, additional, Megalakaki, Aikaterini, additional, Kaiafa, Georgia D, additional, Papoutselis, Menelaos Konstantinos, additional, Sioni, Anastasia, additional, Charchalakis, Nikolaos, additional, Bouronikou, Eleni, additional, Vassilopoulos, George, additional, Lazaris, Vasilios, additional, Spiliotopoulou, Maria, additional, Diamantopoulos, Panagiotis Theodorou, additional, Kontopidou, Flora, additional, Topouzoglou, Zoi, additional, Kalyva, Stamatina, additional, Papadaki, Helen A., additional, Hatzitolios, Apostolos I, additional, Anagnostopoulos, Achilles, additional, Briasoulis, Evangelos, additional, Anagnostopoulos, Nikolaos I., additional, and Symeonidis, Argiris S., additional

Published
2016
Full Text
View/download PDF

27. High incidence of thyroid cancer among patients with acromegaly

Author

Kaldrymidis, Dimitrios, primary, Papadakis, Georgios, additional, Tsakonas, Georgios, additional, Kaldrymidis, Philippos, additional, Flaskas, Theofanis, additional, Seretis, Andreas, additional, Pantazi, Eleni, additional, Kostoglou-Athanassiou, Ifigenia, additional, Peppa, Melpomeni, additional, Roussou, Paraskevi, additional, and Diamanti-Kandarakis, Evanthia, additional

Published
2016
Full Text
View/download PDF

28. Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection

Author

Kountouras, Dimitrios Tsagarakis, Nikolaos J. Fatourou, Evangelia Dalagiorgos, Efthimios Chrysanthos, Nikolaos and Berdoussi, Helen Vgontza, Niki Karagiorga, Markissia and Lagiandreou, Athanasios Kaligeros, Konstantinos Voskaridou, Ersi and Roussou, Paraskevi Diamanti-Kandarakis, Evanthia Koskinas, John

Subjects
virus diseases, digestive system diseases
Abstract

Background Iron overload and hepatitis-C virus (HCV) infection, have been implicated in the evolution of liver disease, in patients with transfusion-dependent beta-thalassaemia major (BTM). However, the impact of these factors in late stages of liver disease in adults with BTM, has not been extensively studied. Aims To investigate serum indices of iron overload, HCV infection and liver disease, in a cohort of 211 adult Greek patients with BTM, in relation with the findings from liver biopsies. Methods In this cross-sectional study, 211 patients with BTM were enrolled and studied, in relation with HCV infection, ferritin, transaminases, chelation treatment and antiviral treatment. Based on 109 patients biopsied, we correlated liver fibrosis, haemosiderosis and inflammation, with serum indices and HCV status Results Among all patients, 74.4% were anti-HCV positive (HCV+). Ferritin was positively correlated with transaminases and negatively correlated with age, while it was not significantly different among HCV+ and HCV patients. Among the HCV+ patients, 55.4% reported antiviral treatment, while genotype 1 predominated. In a subfraction of 109 patients, in which liver biopsy was performed, 89% were HCV+ and 11% HCV. Fibrosis was significantly correlated with age (P=0.046), AST (P=0.004), ALT (P=0.044) and inflammation (P

Published
2013

29. Beta-Thalassemia Major and Female Fertility: The Role of Iron and Iron-Induced Oxidative Stress

Author

Roussou, Paraskevi, Tsagarakis, Nikolaos J., Kountouras, Dimitrios, Livadas, Sarantis, and Diamanti-Kandarakis, Evanthia

Subjects
Article Subject
Abstract

Endocrine complications due to haemosiderosis are present in a significant number of patients with beta-thalassemia major (BTM) worldwide and often become barriers in their desire for parenthood. Thus, although spontaneous fertility can occur, the majority of females with BTM is infertile due to hypogonadotropic hypogonadism (HH) and need assisted reproductive techniques. Infertility in these women seems to be attributed to iron deposition and iron-induced oxidative stress (OS) in various endocrine organs, such as hypothalamus, pituitary, and female reproductive system, but also through the iron effect on other organs, such as liver and pancreas, contributing to the impaired metabolism of hormones and serum antioxidants. Nevertheless, the gonadal function of these patients is usually intact and fertility is usually retrievable. Meanwhile, a significant prooxidants/antioxidants imbalance with subsequent increased (OS) exists in patients with BTM, which is mainly caused by tissue injury due to overproduction of free radicals by secondary iron overload, but also due to alteration in serum trace elements and antioxidant enzymes. Not only using the appropriate antioxidants, essential trace elements, and minerals, but also regulating the advanced glycation end products, could probably reduce the extent of oxidative damage and related complications and retrieve BTM women’s infertility.

Published
2013
Full Text
View/download PDF

30. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.

Author

Angelopoulou, Maria K., Vassilakopoulos, Theodoros P., Batsis, Ioannis, Sakellari, Ioanna, Gkirkas, Konstantinos, Pappa, Vasiliki, Giannoulia, Panagiota, Apostolidis, Ioannis, Apostolopoulos, Christos, Roussou, Paraskevi, Panayiotidis, Panayiotis, Dimou, Maria, Kyrtsonis, Marie‐Christine, Palassopoulou, Maria, Vassilopoulos, Georgios, Moschogiannis, Maria, Kalpadakis, Christina, Margaritis, Dimitrios, Spyridonidis, Alexander, and Michalis, Eurydiki

Subjects
THERAPEUTIC use of immunoglobulins, COMPARATIVE studies, HODGKIN'S disease, IMMUNOGLOBULINS, RESEARCH methodology, MEDICAL cooperation, PROGNOSIS, RESEARCH, SURVIVAL analysis (Biometry), EVALUATION research, TREATMENT effectiveness, RETROSPECTIVE studies
Abstract

This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2-16), and the median time to best response was the fourth cycle. Fifty-seven patients achieved an objective response: twenty-two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty-six (27%) had progressive disease as their best response. At a median follow-up of 11.5 months, median progression-free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P = .005). Bulky disease (P = .01) and response to BV (P <.001) were significant for progression-free survival, while refractoriness to most recent treatment (P = .04), bulky disease (P = .005), and B-symptoms (P = .001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow-up of 13 months. In conclusion, our data indicate that BV is an effective treatment for R/R HL patients even outside clinical trials. Whether BV can cure a fraction of patients remains to be seen. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

31. No significant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years

Author

Kastritis, Efstathios Kyrtsonis, Marie-Christine Hatjiharissi, Evdoxia Symeonidis, Argiris Michalis, Eurydiki Repoussis, Panagiotis Tsatalas, Konstantinos Michael, Michael Sioni, Anastasia Kartasis, Zafiris Stefanoudaki, Ekaterini and Voulgarelis, Michael Delimpasi, Sosana Gavriatopoulou, Maria and Koulieris, Efstathios Gika, Dimitra Vervesou, Elissavet and Konstantopoulos, Konstantinos Kokkini, Garyfalia Zomas, Athanasios Roussou, Paraskevi Anagnostopoulos, Nikolaos and Economopoulos, Theofanis Terpos, Evangelos Zervas, Konstantinos and Dimopoulos, Meletios A. Greek Myeloma Study Grp

Abstract

The treatment of Waldenstrom’s macroglobulinemia (WM) has changed over the last decades, mainly because of the introduction of nucleoside analogues and of rituximab while novel agents such as bortezomib have been recently introduced. We performed an analysis to investigate whether the outcome of patients with WM has improved over the last years, compared to that of patients who started treatment before new drugs became widely available, especially as part of the frontline treatment. We analyzed 345 symptomatic patients with WM: 130 who initiated treatment before and 215 who started treatment after January 1, 2000. Patients who started treatment in the latter group were older and had more often elevated beta2-microglobulin but the other characteristics were similar between the two groups. Most patients who started treatment before January 1, 2000 were treated upfront with alkylating agent-based regimens and most patients who started treatment after January 1, 2000 received rituximab-based regimens as initial treatment. Objective response (63 and 59%, respectively) and median overall survival, OS, (106.5 months for Group A and is estimated at 94 months for Group B, P = 0.327) were similar. There was also no difference regarding OS or cause specific survival (CSS) in each risk group according to IPSSWM. Our observation may be explained by the indolent course of WM in several patients and by the lack of profound cytoreduction in patients with high-risk disease. Possible differences in the 15- or 20-year survival rate between the two groups may be detected with further follow-up of these patients. Am. J. Hematol. 86:479-483, 2011. (C) 2011 Wiley-Liss, Inc.

Published
2011

32. Histological expression of angiogenic factors: VEGF, PDGFR alpha, and HIF-1 alpha in Hodgkin lymphoma

Author

Passam, Freda H. Alexandrakis, Michael G. Kafousi, Maria and Fotinou, Marianthi Darivianaki, Katerina Tsirakis, George and Roussou, Paraskevi A. Stathopoulos, Efstathios N. Siafakas, Nikolaos M.

Abstract

Angiogenesis is a prerequisite for solid tumor growth, but there is relatively limited data regarding Hodgkin lymphoma. The purpose of this study was to examine the immunohistochemical expression of angiogenic and proliferation markers in Hodgkin biopsies in relation to clinical parameters. Immunostaining was performed on 65 Hodgkin biopsies with vascular endothelial growth factor (VEGF), hypoxia inducible factor-1 alpha (HIF-1 alpha), platelet-derived growth factor receptor alpha (PDGFR alpha), Ki-67, and p53. Microvessel density (MVD) was determined by CD31 staining. In all cases, neoplastic cells and reactive background cells were evaluated. The neoplastic population expressed VEGF in 48% of the cases, HIF-1 alpha in 54% of the cases, and PDGFR alpha in 95% of the cases. Both Ki-67 and p53 were positive in neoplastic cells in over 60% of the cases. The MVD had a median of 2.6/0.0625 mm(2) which was not different from normal lymph nodes. VEGF in the non-neoplastic compartment showed increased staining in Ann Arbor stage I-II versus III-IV. In conclusion, VEGF, HIF-1 alpha, and predominantly PDGFRa are expressed in neoplastic cells in the majority of Hodgkin lymphomas. As microvessel formation is not increased in Hodgkin, additional functions of these angiogenic molecules should be investigated. (C) 2008 Elsevier GmbH. All rights reserved.

Published
2009

33. Jumping translocations in hematological malignancies: a cytogenetic study of five cases

Author

Mancila, Kalliopi N. Georgakakos, Vasileios N. Stavropoulou, Chryssa Spyridonidis, Alexandros Angelopoulou, Maria K. and Vlachadami, Ioanna Katsigiannis, Andreas Roussou, Paraskevi and Pantelias, Gabriel E. Sambani, Constantina

Subjects
hemic and lymphatic diseases
Abstract

Jumping translocations (JT) are rare cytogenetic aberrations in hematological malignancies that include unbalanced translocations involving a donor chromosome arm or chromosome segment that has fused to two or more different recipient chromosomes in different cell lines. We report five cases associated with different hematologic disorders and JT to contribute to the investigation of the origin, pathogenesis, and clinical significance of JT These cases involve JT of 1q in a ease of acute myeloblastic leukemia (AML)-M1, a case of Burkitt lymphoma, and a case of BCR/ABL-positive acute lymphoblastic leukemia, as well as a JT of 13q in a case of AML-M5, and a JT of 11q segment in a case of undifferentiated leukemia. TO Our knowledge, with regard to hematologic malignancies, this study presents the first case of JT associated with AML-M1, the first case of JT involving 13q as a donor chromosome, and the first report of JT involving a segment of 11q containing two copies of the MLL gene, jumping on to two recipient chromosomes in each cell line and resulting in six copies of the MLL gene. Our investigation suggests that JT may not contribute to the pathogenesis but rather to the progression of the disease, and it demonstrates that chromosome band 1q10 as a breakpoint of the donor chromosome 1q is also implicated in AML, not. only in multiple myeloma as it has been known until now. (C) 2008 Elsevier Inc. All rights reserved.

Published
2008

34. Rituximab-CHOP (R-CHOP) and radiotherapy (RT) for primary mediastinal large B-cell lymphoma (PMLBCL)

Author

Vassilakopoulos, Theodores P. Angelopoulou, Maria K. Galani, Zacharoula Sachanas, Sotirios Katsigiannis, Andreas and Vrakidou, Effimia Poziopoulos, Christos Constantinou, Nikos and Repoussis, Panayiotis Dimopoulou, Maria N. Kokoris, Stiliani I. and Michali, Evridiki Dimitriadou, Evangelia M. Siakantaris, Marina P. Kontopidou, Flora N. Kalpadaki, Christina Viniou, Nora-Athina Kyriakou, Elias Korkolopoulou, Penelope and Kyrtsonis, Marie-Christine Panayiotidis, Panayiotis Roussou, Paraskevi Pangalis, Gerassimos A.

Published
2006

38. Thymoma with immunodeficiency (Good's syndrome): Review of the literature apropos three cases

Author

Miyakis, Spyridon, Pefanis, Angelos, Passam, Freda H, Christodulakis, George R, Roussou, Paraskevi A, Mountokalakis, Theodoros D, Miyakis, Spyridon, Pefanis, Angelos, Passam, Freda H, Christodulakis, George R, Roussou, Paraskevi A, and Mountokalakis, Theodoros D

Abstract

Good's syndrome is the association of thymoma with immunodeficiency, characterized by hypogammaglobulinaemia, depleted B-cells, diminished T-cells and inversion of the CD4/CD8 ratio. The initial clinical presentation is either with a mass lesion-thymoma that is usually benign, or with recurrent infections due to immunodeficiency. Thymectomy usually favourably affects associated conditions, such as pure red cell aplasia, but does not improve hypogammaglobulinaemia, thus the patient remains dependent on intravenous immune globulin and prone to infections. Infections usually affect the respiratory and/or the gastrointestinal tract. Common respiratory, opportunistic, and eventually life-threatening infections may occur. Moreover, patients with Good's syndrome may present other haematological conditions. We report 3 cases with long follow-up, sharing some common manifestations of the syndrome, but also showing unique features. The principal features of this rare syndrome are further discussed

Published
2006

40. Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care

Author

Vassilakopoulos, Theodoros P., primary, Pangalis, Gerassimos A., additional, Katsigiannis, Andreas, additional, Papageorgiou, Sotirios G., additional, Constantinou, Nikos, additional, Terpos, Evangelos, additional, Zorbala, Alexandra, additional, Vrakidou, Effimia, additional, Repoussis, Panagiotis, additional, Poziopoulos, Christos, additional, Galani, Zacharoula, additional, Dimopoulou, Maria N., additional, Kokoris, Stella I., additional, Sachanas, Sotirios, additional, Kalpadakis, Christina, additional, Dimitriadou, Evagelia M., additional, Siakantaris, Marina P., additional, Kyrtsonis, Marie-Christine, additional, Dervenoulas, John, additional, Dimopoulos, Meletios A., additional, Meletis, John, additional, Roussou, Paraskevi, additional, Panayiotidis, Panayiotis, additional, Beris, Photis, additional, and Angelopoulou, Maria K., additional

Published
2012
Full Text
View/download PDF

41. Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study

Author

Georgiou, George, primary, Roumelioti, Maria, additional, Dimou, Maria, additional, Palaiologou, Danai, additional, Stefanou, Angeliki, additional, Staikou, Efstathia, additional, Kyrtsonis, Marie-Christine, additional, Angelopoulou, Maria K., additional, Vassilakopoulos, Theodoros P., additional, Galani, Zacharoula I, additional, Plata, Eleni, additional, Variami, Eleni, additional, Korantzis, Ioannis, additional, Tsatalas, Konstantinos, additional, Protopapa, Maria, additional, Papaioannou, Maria, additional, Pangalis, Gerasimos, additional, Marinakis, Theodore, additional, Xanthopoulidis, Georgios, additional, Pappi, Vassiliki, additional, Vervesou, Elissavet, additional, Symeonidis, Argiris, additional, Matsouka, Charis, additional, Anargyrou, Konstantinos, additional, Tsionos, Konstantinos, additional, Vyniou, Nora, additional, Gougopoulou, Dimitra, additional, Liapi, Dimitra, additional, Kolokythopoulos, Dionysis, additional, Roussou, Paraskevi, additional, Reppa, Konstantina, additional, Poumbouridou, Eleni, additional, Katodritou, Eirini, additional, Klonizakis, Ioannis, additional, and Panayiotidis, Panayiotis, additional

Published
2011
Full Text
View/download PDF

42. The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function

Author

Dimopoulos, Meletios A., primary, Kastritis, Efstathios, additional, Kyrtsonis, Marie-Christine, additional, Meletis, John, additional, Michalis, Eurydiki, additional, Repoussis, Panagiotis, additional, Tsatalas, Konstantinos, additional, Michael, Michael, additional, Pouli, Anastasia, additional, Kartasis, Zafiris, additional, Stefanoudaki, Ekaterini, additional, Voulgarelis, Michael, additional, Delimpasi, Sosana, additional, Katodritou, Eirini, additional, Symeonidis, Argiris, additional, Gavriatopoulou, Maria, additional, Koulieris, Efstathios, additional, Gika, Dimitra, additional, Zomas, Athanasios, additional, Roussou, Paraskevi, additional, Anagnostopoulos, Nikolaos, additional, Economopoulos, Theofanis, additional, Konstantopoulos, Konstantinos, additional, Parcharidou, Agapi, additional, Zervas, Konstantinos, additional, and Terpos, Evangelos, additional

Published
2010
Full Text
View/download PDF

43. No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years

Author

Kastritis, Efstathios, primary, Kyrtsonis, Marie-Christine, additional, Hadjiharissi, Evdoxia, additional, Symeonidis, Argiris, additional, Michalis, Eurydiki, additional, Repoussis, Panagiotis, additional, Tsatalas, Konstantinos, additional, Michael, Michael, additional, Sioni, Anastasia, additional, Kartasis, Zafiris, additional, Stefanoudaki, Ekaterini, additional, Voulgarelis, Michael, additional, Delimpasi, Sosana, additional, Gavriatopoulou, Maria, additional, Koulieris, Efstathios, additional, Gika, Dimitra, additional, Vervesou, Elissavet, additional, Konstantopoulos, Konstantinos, additional, Kokkini, Garyfalia, additional, Zomas, Athanasios, additional, Roussou, Paraskevi, additional, Anagnostopoulos, Nikolaos, additional, Economopoulos, Theofanis, additional, Terpos, Evangelos, additional, Zervas, Konstantinos, additional, and Dimopoulos, Meletios A., additional

Published
2010
Full Text
View/download PDF

44. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH).

Author

Dimopoulos, Meletios A., primary, Kyrtsonis, Marie-Christine, additional, Hadjiharissi, Evdoxia, additional, Symeonidis, Argiris, additional, Michalis, Eurydiki, additional, Repoussis, Panayiotis, additional, Tsatalas, Costas, additional, Michael, Michalis, additional, Sioni, Anastasia, additional, Stefanoudaki, Ekaterini, additional, Kartasis, Zafiris, additional, Voulgarelis, Michael, additional, Delimpasi, Sosana, additional, Kastritis, Efstathios, additional, Gavriatopoulou, Maria, additional, Koulieris, Efstathios, additional, Gika, Dimitra, additional, Roussou, Paraskevi, additional, Anagnostopoulos, Nikolaos, additional, Terpos, Evangelos, additional, Economopoulos, Theofanis, additional, and Zervas, Konstantinos, additional

Published
2009
Full Text
View/download PDF

46. Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).

Author

Vassilakopoulos, Theodoros P., primary, Angelopoulou, Maria K., additional, Galani, Zacharoula, additional, Sachanas, Sotirios, additional, Katsigiannis, Andreas, additional, Vrakidou, Effimia, additional, Poziopoulos, Christos, additional, Constantinou, Nikos, additional, Repoussis, Panayiotis, additional, Dimopoulou, Maria N., additional, Kokoris, Stiliani I., additional, Michali, Evridiki, additional, Dimitriadou, Evangelia M., additional, Siakantaris, Marina P., additional, Kontopidou, Flora N., additional, Kalpadaki, Christina, additional, Viniou, Nora-Athina, additional, Kyriakou, Elias, additional, Korkolopoulou, Penelope, additional, Kyrtsonis, Marie-Christine, additional, Panayiotidis, Panayiotis, additional, Roussou, Paraskevi, additional, and Pangalis, Gerassimos A., additional

Published
2006
Full Text
View/download PDF

48. Excellent Outcome with Rituximab-CHOP (R-CHOP) Combined with Radiotherapy (RT) in Primary Mediastinal Large B-Cell Lymhoma (PMLBCL).

Author

Vassilakopoulos, Theodoros P., primary, Angelopoulou, Maria K., primary, Galani, Zacharoula, primary, Sachanas, Sotirios, primary, Katsigiannis, Andreas, primary, Dimopoulou, Maria N., primary, Kokoris, Styliani I., primary, Michalis, Evridiki, primary, Dimitriadou, Evangelia M., primary, Siakantaris, Marina P., primary, Kontopidou, Flora N., primary, Kalpadakis, Christina, primary, Sarantopoulos, Angelos, primary, Korkolopoulou, Pinelopi, primary, Roussou, Paraskevi, primary, and Pangalis, Gerassimos A., primary

Published
2005
Full Text
View/download PDF

49. Hypothalamic-pituitary-adrenal axis dysfunction in critically ill patients with traumatic brain injury: Incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin-6 levels*

Author

Dimopoulou, Ioanna, primary, Tsagarakis, Stylianos, additional, Kouyialis, Andreas T., additional, Roussou, Paraskevi, additional, Assithianakis, Georgios, additional, Christoforaki, Marietta, additional, Ilias, Ioannis, additional, Sakas, Damianos E., additional, Thalassinos, Nikolaos, additional, and Roussos, Charis, additional

Published
2004
Full Text
View/download PDF

50. A Randomized Trial Comparing Intensified CNOP vs. CHOP in Patients with Aggressive Non-Hodgkin's Lymphoma

Author

Pangalis, Gerassimos A., primary, Vassilakopoulos, Theodoros P., additional, Michalis, Evridiki, additional, Roussou, Paraskevi, additional, Vrakidou, Effimia, additional, Repousis, Panayiotis, additional, Angelopoulou, Maria K., additional, Siakantaris, Marina P., additional, Korantzis, John, additional, Symeonidis, Argyrios, additional, Grigorakis, Vassiliki, additional, Stefanoudakis, Ekaterini, additional, Stamatellou, Marina, additional, Bourantas, Konstantinos L., additional, Kalmantis, Themis, additional, Christopoulos, George, additional, Kokkinis, Garyfallia, additional, Mihalakeas, Ilias, additional, and Papayiannis, Antonios, additional

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results